Trial Profile

A Phase 1/2, Open-label Study Investigating the Safety, Tolerability and Efficacy of ASP7517 as a Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors Known to Express WT1 Antigen

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 18 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ASP 7517 (Primary) ; Pembrolizumab (Primary)
Indications Colorectal cancer; Malignant melanoma; Ovarian cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use
Sponsors Astellas Pharma Global Development

24 Jul 2024 Status changed from active, no longer recruiting to completed.
23 Feb 2024 Planned End Date changed from 31 Dec 2027 to 30 Jun 2024.
23 Feb 2024 Planned primary completion date changed from 31 Dec 2027 to 30 Jun 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com